胃と腸46巻13号

2011年12月発行

今月の主題 難治性潰瘍性大腸炎─診療・治療の新たな展開 ノート

難治性潰瘍性大腸炎と5-ASA製剤―大量療法を中心に

著者： 渡辺憲治¹ 新藤正喜¹ 塚原卓矢¹ 伊藤良恵¹ 森本謙一¹ 野口篤志¹ 杉森聖司¹ 鎌田紀子¹ 十河光栄¹ 町田浩久¹ 岡崎博俊¹ 谷川徹也¹ 山上博一¹ 富永和作¹ 渡辺俊雄¹ 藤原靖弘¹ 荒川哲男¹

所属機関： ¹大阪市立大学大学院医学研究科消化器内科学

ページ範囲：P.2009 - P.2015

要旨　潰瘍性大腸炎の治療の基本となる各種5-アミノサリチル酸（5-ASA）製剤の特徴と，それらの高用量投与による寛解導入療法，寛解維持療法について述べた．5-ASA製剤も今後新規薬剤の導入が見込まれるが，サラゾスルファピリジンも副作用さえ生じなければ有用性が残されている．5-ASA製剤による治療のキーワードは送達性と用量であり，安全性が高く用量依存性の5-ASA製剤による高用量投与は，寛解導入療法のみならず寛解維持療法においても有用性を発揮する可能性があり，ステロイド，血球成分除去療法，免疫調節剤の使用前に試みておくべき治療法である．

参考文献

1）Baron JH, Connell AM, Lennard-Jones JE, et al. Sulphasalazine and salicylazosulphadimidine in ulcerative colitis. Lancet 1 : 1094-1096, 1962

2）Das KM, Eastwood MA, McManus JP, et al. Adverse reactions during salicylazosulfapyridine therapy and the relation with drug metabolism and acetylator phenotype. N Engl J Med 289 : 491-495, 1973

3）Frieri G, Giacomelli R, Pimpo M, et al. Mucosal 5-aminosalicylic acid concentration inversely correlates with severity of colonic inflammation in patients with ulcerative colitis. Gut 47 : 410-414, 2000

4）Naganuma M, Iwao Y, Ogata H, et al. Measurement of colonic mucosal concentrations of 5-aminosalicylic acid is useful for estimating its therapeutic efficacy in distal ulcerative colitis : comparison of orally administered mesalamine and sulfasalazine. Inflamm Bowel Dis 7 : 221-225, 2001

5）上野文昭．潰瘍性大腸炎における5-ASA製剤開発の変遷─エビデンスからの考察．新薬と臨 59 : 2241-2255, 2010

6）Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 19 : CD000543, 2006

7）Sutherland L, Macdonald JK. Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev 19 : CD000544, 2006

8）Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology 132 : 66-75, 2007

9）Kruis W, Bar-Meir S, Feher J, et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis : a dose-finding study with newly developed mesalamine. Clin Gastroenterol Hepatol 1 : 36-43, 2003

10）Hanauer SB, Sandborn WJ, Kornbluth A, et al. Delayed-release oral mesalamine at 4.8g/day（800mg tablet）for the treatment of moderately active ulcerative colitis : the ASCEND II trial. Am J Gastroenterol 100 : 2478-2485, 2005

11）Hanauer SB, Sandborn WJ, Dallaire C, et al. Delayed-release oral mesalamine 4.8g/day（800mg tablets）compared to 2.4g/day（400mg tablets）for the treatment of mildly to moderately active ulcerative colitis : The ASCEND I trial. Can J Gastroenterol 21 : 827-834, 2007

12）Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8g/day（800-mg tablet）is effective for patients with moderately active ulcerative colitis. Gastroenterology 137 : 1934-1943, 2009

13）Hiwatashi N, Suzuki Y, Mitsuyama K, et al. Clinical trial : Effects of an oral preparation of mesalazine at 4g/day on moderately active ulcerative colitis. A phase III parallel-dosing study. J Gastroenterol 46 : 46-56, 2011

14）Yamamoto T, Umegae S, Matsumoto K. High-dose mesalazine treatment for ulcerative colitis patients who relapse under low-dose maintenance therapy. Dig Liver Dis 43 : 386-390, 2011

15）Ford AC, Achkar JP, Khan KJ, et al. Efficacy of 5-aminosalicylates in ulcerative colitis : systematic review and meta-analysis. Am J Gastroenterol 106 : 601-616, 2011

16）Miner P, Hanauer S, Robinson M, et al. Safety and efficacy of controlled-release mesalamine for maintenance of remission in ulcerative colitis. Pentasa UC Maintenance Study Group. Dig Dis Sci 40 : 296-304, 1995

17）Gisbert JP, González-Lama Y, Maté J. 5-Aminosalicylates and renal function in inflammatory bowel disease : a systematic review. Inflamm Bowel Dis 13 : 629-638, 2007